Improving Drug Abuse Treatment by Research and Training

通过研究和培训改善药物滥用治疗

• 批准号: 7147899
• 负责人: Herbert David Kleber
• 金额: $ 12.31万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7147899
• 关键词: Cannabis; buprenorphine; cocaine; detoxification; drug abuse chemotherapy; drug abuse therapy; drug withdrawal; heroin; human subject; human therapy evaluation; marijuana abuse; naltrexone; patient oriented research

DESCRIPTION (provided by applicant): The overall aim of this K-05 renewal is to support and expand the applicant's work in developing and improving pharmacotherapy for substance abuse as well as mentoring scientists embarking on such a career. The applicant has had a productive career in both areas, first at Yale and then Columbia University. The current K-05 was awarded in 2001 and enabled the applicant to leave his half-time position as Medical Director of CASA, a policy research center, and devote full time to his biomedical research and training activities at Columbia. Being at Columbia full- time made it possible for the applicant to expand his role in research, research oversight, and mentoring of faculty and trainees in the growing Division on Substance Abuse, which he directs. In these 4 years, aided by the effort of these talented faculty the Division continued to carry out the high quality of research it had begun and even expanded its scope. The applicant's current research focuses on developing and improving medications for treating cocaine, heroin, and marijuana dependence. Current funding for these areas is in hand for the first 3 years of this award since his Medication Development Center grant was recently renewed until September 2009. The Center includes 5 projects and two Cores, one of which funds innovative pilot projects. The Center Projects include: 1) human laboratory for studying opioids. Its current focus is on the rapidly rising problem of prescription opioids and will characterize the reinforcing efficacy of a number of different commonly abused opioid medications and the utility of buprenorphine to block/reduce these effects. 2) Imaging studies on cocaine which focus on relapse and the role of D-1 receptors and kappa opioid receptors. 3) A clinical trial with depressed cocaine abusers, the most common co-occurring disorder in cocaine. It examines not only the medication effect but also how to better identify which patients need such treatment and how to enhance it. 4) Agonist therapy for marijuana dependency. This is the first large placebo-controlled trial of an agonist agent for this common dependence, which is underestimated both in frequency and difficulty in stopping. 5) A human laboratory study on marijuana using a variety of agents, either to diminish withdrawal or to prevent relapse. In addition to the Center, the applicant will be developing projects relating to buprenorphine induction and withdrawal. Finally, he will continue active mentoring of young scientists and training at the medical student, resident, fellow, and young faculty levels.

描述（由申请人提供）：本次 K-05 更新的总体目标是支持和扩展申请人在开发和改进药物滥用药物治疗方面的工作，并指导从事此类职业的科学家。申请人首先在耶鲁大学，然后在哥伦比亚大学，在这两个领域都取得了卓有成效的职业生涯。目前的K-05于2001年授予，使申请人能够辞去政策研究中心CASA医学主任的半职，全职投入哥伦比亚大学的生物医学研究和培训活动。全职在哥伦比亚大学工作使申请人能够在他所领导的不断壮大的药物滥用部门中扩大他在研究、研究监督以及对教师和实习生的指导方面的作用。在这四年里，在这些才华横溢的教师的努力帮助下，该部门继续开展已经开始的高质量研究，甚至扩大了范围。申请人目前的研究重点是开发和改进治疗可卡因、海洛因和大麻依赖的药物。自从他的药物开发中心拨款最近更新至 2009 年 9 月以来，这些领域的当前资金已用于该奖项的前 3 年。该中心包括 5 个项目和两个核心项目，其中一个为创新试点项目提供资金。该中心的项目包括：1）研究阿片类药物的人体实验室。目前的重点是处方阿片类药物迅速上升的问题，并将描述许多不同的常见滥用阿片类药物的增强功效以及丁丙诺啡阻止/减少这些影响的效用。 2) 可卡因的影像学研究，重点关注复发以及 D-1 受体和 kappa 阿片受体的作用。 3) 一项针对抑郁可卡因滥用者的临床试验，这是可卡因中最常见的并发疾病。它不仅检查药物效果，还检查如何更好地识别哪些患者需要这种治疗以及如何加强治疗。 4) 大麻依赖激动剂治疗。这是针对这种常见依赖性的激动剂的第一个大型安慰剂对照试验，这种依赖性的频率和停止难度都被低估了。 5）一项针对大麻的人类实验室研究，使用多种药物来减少戒断或防止复发。除该中心外，申请人还将开发与丁丙诺啡诱导和戒断相关的项目。最后，他将继续积极指导年轻科学家，并在医学生、住院医生、研究员和年轻教师层面进行培训。